MorphoSys AG (WBO:MOR) Price-to-Owner-Earnings : (As of Apr. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Price-to-Owner-Earnings?

As of today (2024-04-28), MorphoSys AG's share price is €67.80. MorphoSys AG does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for MorphoSys AG's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of MorphoSys AG was 667.34. The lowest was 11.82. And the median was 25.85.

WBO:MOR's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), MorphoSys AG's share price is €67.80. MorphoSys AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.52. Therefore, MorphoSys AG's PE Ratio for today is At Loss.

As of today (2024-04-28), MorphoSys AG's share price is €67.80. MorphoSys AG's EPS without NRI for the trailing twelve months (TTM) ended in was €-6.19. Therefore, MorphoSys AG's PE Ratio without NRI for today is At Loss.

During the past 13 years, MorphoSys AG's highest PE Ratio without NRI was 254.41. The lowest was 0.00. And the median was 72.29.

MorphoSys AG Price-to-Owner-Earnings Historical Data

The historical data trend for MorphoSys AG's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Price-to-Owner-Earnings Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Owner-Earnings

Get a 7-Day Free Trial

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	-	26.99	23.76	-

Competitive Comparison of MorphoSys AG's Price-to-Owner-Earnings

For the Biotechnology subindustry, MorphoSys AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Price-to-Owner-Earnings falls into.

MorphoSys AG Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

MorphoSys AG's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	67.80	/	-7.01
	=

MorphoSys AG (WBO:MOR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

MorphoSys AG Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.